SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Acadia Pharmaceuticals Q3 Revenue Rises 23% on DAYBUE, NUPLAZID Sales

Acadia Pharmaceuticals reported a 23% rise in third-quarter revenue, citing DAYBUE and NUPLAZID sales.

ACAD

Related stories